Beone Medicines (ONC) reported $5.3B in revenue for fiscal 2025, +40.2% year on year. That ranks #775 by revenue among 2853 SEC filers and #67 in Healthcare. Net income was $287M, a net margin of 5.4%. Revenue has grown 72.8% a year on average since 2014 ($13.0M then). The fiscal 2025 balance sheet shows $8.2B in total assets, $4.5B in cash and $962M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $5.3B | +40.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $4.7B | +45.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $447M | +$1.0B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $287M | +$932M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.1B | +$1.3B | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $186M | −62.3% | FY20252025-12-31 |
| Total assetsAssets | $8.2B | +38.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $4.4B | +30.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $4.5B | +73.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $962M | +477.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $1.5B | $227M | Open → |
| Q2 20262026-06-30 | $1.7B | $237M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 85 of 161 companies compared | 5.4% | |
| Operating marginRank 94 of 160 companies compared | 8.4% | |
| R&D as share of revenueRank 8 of 102 companies compared | 40.2% | |
| Cash as share of revenueRank 4 of 160 companies compared | 85.1% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Beone Medicines Ltd.
- Ticker
- ONC
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001651308
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Encompass HealthEHC | $5.9B | $566M |
| Agilon HealthAGL | $5.9B | −$391M |
| Option Care HealthOPCH | $5.6B | $208M |
| Beone MedicinesONC | $5.3B | $287M |
| Pacs GroupPACS | $5.3B | $192M |
| ResmedRMD | $5.1B | $1.4B |
| IncyteINCY | $5.1B | $1.3B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Beone Medicines — Key figures |url=https://companiesranked.com/en/company/beone-medicines |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Beone Medicines — Key figures. CompaniesRanked. https://companiesranked.com/en/company/beone-medicinesBibTeX
@misc{companiesranked-en-company-beone-medicines-2026,
author = {{CompaniesRanked}},
title = {{Beone Medicines — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/beone-medicines}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-011946 · February 26, 2026
{{cite web |title=Beone Medicines — Key figures — 10-K (0001628280-26-011946) |url=https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.